Menu
Search Close

News

Final Results for the year ended 30 April 2010

14th July 2010

Scancell Holdings plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, announces its final results for the year ended 30 April 2010.

Highlights:

  • Strong progress in the development of the Company’s lead therapeutic melanoma vaccine SCIB1
  • Successful fundraising of £2.54 million (gross) during 2010
  • Loss before tax for the year of £1.80 million (2009: £0.8 million)
  • Cash at year end of £2.83 million
  • Since the year end the Company commenced Phase I/IIa clinical trials in humans for SCIB1

The Directors of the issuer accept responsibility for this announcement.

For further information contact:

Professor Lindy Durrant, (CEO)  -  Scancell Holdings Plc:

  • +44 (0)207 245 1100

John Bick/Kirsty Corcoran  -  Hansard Communications

  • +44 (0)207 245 1100
  • +44 (0)7872 061 007

Ross Andrews/Tom Rowley  -  Zeus Capital

  • +44 (0)161 831 1512

View the full document

Webcasts, Interviews and Media Coverage

Scancell to begin dosing in UK phase II trial of flagship skin cancer drug

Cliff Holloway, CEO of Scancell Holdings PLC (LON:SCLP), speaks to Proactive London's Andrew Scott after announcing they're to kick off the UK arm of the phase II clinical trial of its flagship skin cancer drug.

The study will test the safety and efficacy of SCIB1 in 25 metastatic melanoma patients who are also receiving Merck’s checkpoint inhibitor Pembrolizumab.

Thu, 25 Apr 2019 10:56:00

Scancell higher as it is to begin UK arm of phase II skin cancer trial within weeks

The mid-stage study is testing Scancell’s flagship skin cancer immunotherapy in combination with Keytruda – the blockbuster checkpoint inhibitor developed by Merck

Thu, 25 Apr 2019 12:20:00

Scancell Holdings wins Japanese patent protection

It follows on from similar awards in key markets such as the US, Europe, South Africa and Australia

Mon, 08 Apr 2019 08:20:00